NASDAQ · BGM
Healthcare · Drug Manufacturers - Specialty & Generic
$9.54
Down-$1.09 (-11.43%)
Updated Nov 3, 2026, 6:24 PM
SID Score
5.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · BGM
1M range · 18 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
BGM closed at $9.54 after 18 trading sessions, up 2.03% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $9.7999 | $9.87 | $9.476 | $9.54 | 2.22K |
| Oct 28, 2026 | $8.70 | $9.725 | $8.11 | $9.725 | 7.05K |
| Oct 27, 2026 | $8.55 | $8.975 | $8.55 | $8.975 | 2.78K |
| Oct 26, 2026 | $7.75 | $8.8699 | $7.75 | $8.40 | 10.75K |
| Oct 23, 2026 | $8.49 | $9.79 | $7.70 | $7.85 | 54.63K |
| Oct 22, 2026 | $8.65 | $10.66 | $7.70 | $8.20 | 39.6K |
| Oct 21, 2026 | $8.24 | $8.24 | $8.22 | $8.24 | 1.18K |
| Oct 19, 2026 | $9.35 | $9.35 | $8.05 | $8.97 | 5.98K |
| Oct 16, 2026 | $8.72 | $8.94 | $8.65 | $8.65 | 2.85K |
| Oct 15, 2026 | $8.59 | $8.59 | $8.59 | $8.59 | 663.78 |
| Oct 14, 2026 | $10.10 | $10.29 | $9.55 | $9.55 | 13.48K |
| Oct 13, 2026 | $9.56 | $10.48 | $9.56 | $10.48 | 5.31K |
| Oct 12, 2026 | $10.74 | $10.74 | $9.60 | $10.20 | 8.96K |
| Oct 9, 2026 | $9.95 | $10.78 | $9.95 | $10.75 | 3.27K |
| Oct 8, 2026 | $9.38 | $9.96 | $9.38 | $9.96 | 1.45K |
| Oct 7, 2026 | $9.47 | $9.61 | $8.68 | $9.39 | 1.76K |
| Oct 6, 2026 | $9.17 | $10.08 | $9.17 | $9.65 | 7.77K |
| Oct 5, 2026 | $9.28 | $9.35 | $8.3575 | $9.35 | 4.58K |
The latest Smart Investors Daily articles mentioning BGM.
Company
Market Activity
Research & News
BGM research
Company profile and research snapshot.
BGM Group Ltd is a biopharmaceuticals, bio-extraction, and medical health business. Its product range includes oxytetracycline APIs, licorice preparations, and crude heparin sodium. Maximum revenue is from Oxytetracycline & Licorice and TCMD, followed by Heparin products and Sausage casing.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Sep 23, 2026
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 56.3% to $6.47 during Wednesday's pre-market session. The company's market cap stands at $2.5 million. Vistagen Therapeutics (NASDAQ:VTGN) shares increased by
Benzinga · Jul 30, 2026
-SEC Filing
Benzinga · Feb 26, 2026
BGM Group Ltd. (NASDAQ: BGM) (the "Company" or "BGM") announced on February 24, 2026, that it has received a notification (the "Notification") from the Listing Qualifications Department of The Nasdaq Stock Market
seekingalpha.com · Sep 24, 2025
32.7% of BGM's revenue is now from high-growth AI, pushing profit up 78%. Yet, the market still values it like a slow-moving API business. With β ≈ 0.04–0.05 and basically no leverage, you get CAPM ≈ 4.42% and WACC ≈ 4.41%, that math checks out. On my assumptions, the DCF lands at about $19.07 per share. Versus the current $8.93, that's roughly +113% upside—consistent with the "undervalued" call.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BGM.
